Nel ASA

DiaGenic ASA - Timeline rights issue with preferential rights

With reference to stock exchange notifications 22 January and 25

February 2014 and in accordance with the resolution at the Extraordinary

General Meeting held today 25 February 2014 shares in DiaGenic ASA will

be traded ex subscription rights in connection with the planned rights

issue as of tomorrow 26 February 2014.

The subscription period for the rights issue is expected to be from on

or about 17 March 2014 to on or about 31 March 2014 at 16:30 hours CET.

Trading in the subscription rights is expected to commence on Oslo Børs

or about 17 March 2014 and end on or about 28 March 2014 at 16:30 hours

(CET).

The subscription price will be NOK 0.50 per new share and each eligible

shareholder will be granted 12.25509 subscription rights for each share

registered as held by such eligible shareholder as of the record date 28

February 2014.

Contact:

Ruben Ekbråten, Acting CEO

Telephone: 47 2324 8950

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to

create value for patients, partners and investors by developing

innovative and patient friendly in vitro diagnostic (IVD) products for

early detection of diseases. The company's proprietary concept implies

that a disease evokes systemic responses in the blood unique for the

disease, and which can be measured by using a blood sample. DiaGenic is

a world leader in identifying gene expression signatures in blood and is

focused on the development of IVD biomarker products in the field of

Alzheimer's disease. The company protects its technology through an

extensive patent portfolio. DiaGenic is listed on the Oslo Stock

Exchange. For more information please visit: www.diagenic.com

AI Terminal